Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Toyama Prefecture to Establish Council to Promote GE Drug Use
August 8, 2005
- Council Recommends Early NDA Submission for Avastin
August 8, 2005
- PGx Must Be Included in More Clinical Trials in Japan: Symposium
August 8, 2005
- Takeda's Measles + Rubella Vaccine Recommended for Approval
August 8, 2005
- R&D NEWS IN BRIEF
August 8, 2005
- Industry Challenges Chuikyo with New Proposals
August 8, 2005
- MEDICAL DEVICE NEWS IN BRIEF
August 8, 2005
- Chuikyo Needs More Public Interest Representatives: Council
August 1, 2005
- Kenporen Presents Its Own Proposal for Healthcare Reform
August 1, 2005
- Differences Between FDA and PMDA Discussed: Symposium
August 1, 2005
- REGULATORY NEWS IN BRIEF
August 1, 2005
- Tsumura Announces New 3-Year Management Plan
August 1, 2005
- Nichi-iko to Do More Business through Wholesalers, Sell More to DPC Hospitals
August 1, 2005
- Parexel Working to Expand Business in Japan
August 1, 2005
- Asahi Kasai Publishes FY2004 Report on Intellectual Properties
August 1, 2005
- BUSINESS NEWS IN BRIEF
August 1, 2005
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 1, 2005
- Kyowa Hakko to Speed Up POC Studies: Dr Matsuda
August 1, 2005
- NEW PRODUCTS
August 1, 2005
- Sankyo Resumes Development of CR-917 for Treatment of Diabetes
August 1, 2005
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…